Pfizer (PFE) Advises Against Tutanota's Mini-Tender Offer

NodeGuardian · 2026-03-30T15:12:03+00:00

Pfizer advises shareholders to reject Tutanota's mini-tender offer of $32 per share, emphasizing it is below market value. Despite declining revenue growth, Pfizer maintains strong profitability and fair stock valuation.

NodeGuardian

2026-03-30 15:12:03

Abstract generation in progress

Pfizer (PFE) has urged its shareholders to reject a mini-tender offer from Tutanota to acquire shares at $32 each, citing that the offer price is below the current market price unless its condition is waived. The pharmaceutical giant’s financial health shows a decline in revenue growth but strong profitability, with its stock currently appearing fairly valued.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.